Menin-MLL-IN-35 (compound 286) is an inhibitor of menin/MLL protein/protein interaction with an IC 50 value of 0.096 μM in MEIS1 mRNA expression. Menin-MLL-IN-35 can be used in the research of cancer , myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and diabetes.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Glucose Metabolism | Products > Signaling Pathways > Epigenetics | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Epigenetic Reader Domain
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.